Table 4.

Ninety-Day Outcomes

	rt-PA+Eptifibatide (n=101)	rt-PA (n=25)	Unadjusted Odds Ratio (95% CI)	Adjusted* Odds Ratio (95% CI)	P Value Unadjusted/ Adjusted
Prespecified primary efficacy outcome measure
mRS 0–1 or return to baseline, n (%)	50 (49.5)	9 (36.0)	1.74 (0.70–4.31)	1.37 (0.51–3.71)	0.23/0.53
Other efficacy end points
mRS 0–1 only, n (%)	44 (43.6)	6 (24.0)	2.44 (0.90–6.64)	1.98 (0.67–5.88)	0.07/0.22
Barthel Index of ≥95, n (%)	55 (54.5)	11 (44.0)	1.52 (0.63–3.67)	1.10 (0.40–3.02)	0.35/0.85
Glasgow Outcome Scale of 1, n (%)	52 (51.5)	10 (40.0)	1.59 (0.65–3.88)	1.19 (0.44–3.24)	0.30/0.73
New stroke within 90 d, n (%)	1 (1.0)	0 (0.0)			1.00

CI indicates confidence interval; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and rt-PA, recombinant tissue plasminogen activator.

^*Adjusted for age, baseline NIHSS and time to IV rt-PA.